ASCO

News

ASCO26: DNA test could spare breast cancer patients chemo

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

Patients

ASCO 26: War, disasters, policy compound cancer care challen...

A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

ASCO26: Big win for Erleada in perioperative prostate cancer

ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.

News

ASCO26: Revolution's 'grand slam' data in pancreatic cancer

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

ASCO26: DNA test could spare breast cancer patients chemo

ASCO 26: War, disasters, policy compound cancer care challen...

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

ASCO26: Big win for Erleada in perioperative prostate cancer

ASCO26: Revolution's 'grand slam' data in pancreatic cancer

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

ASCO

Editor's Picks